# Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

> **NCT00240266** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 15 (—)

## Conditions studied

- Metabolic Syndrome
- Dyslipidemia

## Interventions

- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT00240266
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2004-11
- **Final completion:** 2004-12
- **Target enrollment:** 15 (—)
- **Last updated:** 2010-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240266, "Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00240266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*